SCHEMBL6130697

SCHEMBL6130697

SCSC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 19/20 0.56
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11788458 0.76 TAAR1 (0.41) KIF11
Ethyl(Trityl)Sulfane SCHEMBL4755270 0.75 KIF11 (0.56) KIF11
SCHEMBL5545280 0.75 KIF11 (0.56) KIF11
SCHEMBL5357811 0.74 KIF11 (0.55) KIF11
Ethyl(Trityl)Sulfane SCHEMBL2772809 0.73 KIF11 (0.54) KIF11
Benzyl(Trityl)Sulfane SCHEMBL7543647 0.73 KIF11 (0.54) KIF11
Cysteamine SCHEMBL3970283 0.73 KIF11 (0.81) KIF11
SCHEMBL1010720 0.72 KIF11 (0.56) KIF11
SCHEMBL38315 0.71 KIF11 (1.00) KIF11
Ethyl(Trityl)Sulfane SCHEMBL16908567 0.71 KIF11 (0.52) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050064468-A1 concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports IBC ADVANCED TECHNOLOGIES, INC. 2005-03-24 US disclosed
EP-1453602-A4 COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES IBC ADVANCED TECH INC (US) 2005-01-12 EP disclosed
EP-1453602-A2 COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES IBC ADVANCED TECHNOLOGIES, INC. (US) 2004-09-08 EP disclosed
US-6774082-B2 COMPOSITION FOR USE IN THE SEPARATION OF PREFERENTIAL BIOPOLYMERS FROM SAMPLE IBC ADVANCED TECHNOLOGIES, INC. 2004-08-10 US disclosed
US-20030050458-A1 Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences IBC ADVANCED TECHNOLOGIES, INC. 2003-03-13 US disclosed
WO-2002092766-A2 COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES IBC ADVANCED TECHNOLOGIES, INC. (US) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050458-A1 Compositions and methods for separating heterocyclic aromatic amine bases, nucleosides, nucleotides, and nucleotide sequences NUDT1, ATIC, PNP KIF11 2825/4885IDO1 464/4885
US-20050064468-A1 concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports NUDT1, PCNA, NSUN2 KIF11 2903/4885IDO1 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.